Compare AbbVie Inc (ABBV) vs Ralph Lauren Corp (RL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Ralph Lauren Corp — how do they compare? AbbVie Inc trades at $252.9 (market cap $449.91B), while Ralph Lauren Corp trades at $385.79 (market cap $23.53B). The key difference: AbbVie Inc is far larger — about 19.1× Ralph Lauren Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | RL | |
|---|---|---|
Market Cap | $449.91B | $23.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $414.25 |
52-Week Low | $184.85 | $283.34 |
Enterprise Value | $513.38B | $24.47B |
Dividend Yield | 2.72% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Ralph Lauren (RL) trades at $395.31, down 0.73% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.80 surpassing expectations. Revenue growth accelerated to $7.08 billion in 2025, while net income margin improved to 10.49%. Analyst consensus remains strongly bullish with a $446.25 price target, representing 13% upside potential from current levels.
RL presents a compelling growth story with expanding margins and strategic initiatives driving performance. Key risks include consumer discretionary spending sensitivity and competitive pressures in the apparel sector. The company's digital expansion and Next Great Chapter strategy provide catalysts for continued outperformance, though macroeconomic headwinds could impact near-term results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
